Suppr超能文献

下一代疫苗:基于纳米颗粒的 DNA 和 mRNA 递送。

Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.

机构信息

Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.

Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, P. R. China.

出版信息

Adv Healthc Mater. 2021 Apr;10(8):e2001812. doi: 10.1002/adhm.202001812. Epub 2021 Jan 18.

Abstract

Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are delivered to the body to generate proteins, which mimic disease antigens to stimulate the immune response. Advantages of nucleic acid vaccines include stimulation of both cell-mediated and humoral immunity, ease of design, rapid adaptability to changing pathogen strains, and customizable multiantigen vaccines. To combat the SARS-CoV-2 pandemic, and many other diseases, nucleic acid vaccines appear to be a promising method. However, aid is needed in delivering the fragile DNA/mRNA payload. Many delivery strategies have been developed to elicit effective immune stimulation, yet no nucleic acid vaccine has been FDA-approved for human use. Nanoparticles (NPs) are one of the top candidates to mediate successful DNA/mRNA vaccine delivery due to their unique properties, including unlimited possibilities for formulations, protective capacity, simultaneous loading, and delivery potential of multiple DNA/mRNA vaccines. This review will summarize the many varieties of novel NP formulations for DNA and mRNA vaccine delivery as well as give the reader a brief synopsis of NP vaccine clinical trials. Finally, the future perspectives and challenges for NP-mediated nucleic acid vaccines will be explored.

摘要

核酸疫苗是一种免疫接种方法,旨在引起类似于减毒活疫苗的免疫反应。在这种方法中,将 DNA 或信使 RNA(mRNA)序列递送到体内以产生蛋白质,这些蛋白质模拟疾病抗原以刺激免疫反应。核酸疫苗的优点包括刺激细胞介导和体液免疫、易于设计、快速适应病原体菌株的变化以及可定制的多抗原疫苗。为了应对 SARS-CoV-2 大流行和许多其他疾病,核酸疫苗似乎是一种很有前途的方法。然而,在递送电镜下脆弱的 DNA/mRNA 有效载荷方面仍需要援助。已经开发了许多输送策略来引发有效的免疫刺激,但没有一种核酸疫苗获得 FDA 批准用于人体使用。由于其独特的性质,纳米颗粒(NPs)是介导成功的 DNA/mRNA 疫苗输送的首选候选者之一,这些性质包括制剂的无限可能性、保护能力、同时加载以及输送多种 DNA/mRNA 疫苗的潜力。本文综述了用于 DNA 和 mRNA 疫苗输送的新型 NP 制剂的多种变体,并简要概述了 NP 疫苗临床试验。最后,探讨了 NP 介导的核酸疫苗的未来前景和挑战。

相似文献

1
Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.下一代疫苗:基于纳米颗粒的 DNA 和 mRNA 递送。
Adv Healthc Mater. 2021 Apr;10(8):e2001812. doi: 10.1002/adhm.202001812. Epub 2021 Jan 18.
4
Advancements in protein nanoparticle vaccine platforms to combat infectious disease.蛋白质纳米颗粒疫苗平台在传染病防治方面的进展。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1681. doi: 10.1002/wnan.1681. Epub 2020 Nov 8.
6
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新:挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
10
Current Status and Future Perspectives on MRNA Drug Manufacturing.信使核糖核酸药物制造的现状与未来展望
Mol Pharm. 2022 Apr 4;19(4):1047-1058. doi: 10.1021/acs.molpharmaceut.2c00010. Epub 2022 Mar 3.

引用本文的文献

本文引用的文献

4
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
7
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
9
Nanoparticle depots for controlled and sustained gene delivery.纳米颗粒库用于控制和持续的基因传递。
J Control Release. 2020 Jun 10;322:622-631. doi: 10.1016/j.jconrel.2020.03.021. Epub 2020 Mar 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验